Spero Therapeutics Files 8-K
Ticker: SPRO · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001, $52.9 million, $20,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting
TL;DR
Spero Therapeutics dropped an 8-K detailing operational results and exec changes.
AI Summary
Spero Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting on events as of January 7, 2025. The filing includes information on results of operations, financial condition, and changes in directors or officers. It also covers Regulation FD disclosures, other events, and financial statements.
Why It Matters
This 8-K filing provides updates on Spero Therapeutics' operational and financial status, as well as any significant changes in its leadership or corporate governance.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing standard corporate updates and does not appear to contain material adverse information.
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- January 7, 2025 (date) — Earliest event reported
- January 10, 2025 (date) — Date of report
FAQ
What specific events are detailed in the 'Results of Operations and Financial Condition' section?
The filing indicates that results of operations and financial condition are discussed, but the specific details are not provided in the provided text.
Were there any departures or appointments of directors or officers reported?
Yes, the filing explicitly lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of information.
Does the filing include any Regulation FD disclosures?
Yes, 'Regulation FD Disclosure' is listed as an item of information in the filing.
What is the SIC code for Spero Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Spero Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was Spero Therapeutics, Inc. formerly known as Spero Therapeutics, LLC?
The company was formerly known as Spero Therapeutics, LLC, and the date of the name change was March 16, 2017.
Filing Stats: 1,884 words · 8 min read · ~6 pages · Grade level 11.9 · Accepted 2025-01-10 07:00:51
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se
- $52.9 million — h and cash equivalents of approximately $52.9 million (unaudited) as of December 31, 2024. Th
- $20,000 — receive additional cash compensation of $20,000 per month while she serves as the Inter
Filing Documents
- d820907d8k.htm (8-K) — 43KB
- d820907dex101.htm (EX-10.1) — 10KB
- d820907dex102.htm (EX-10.2) — 16KB
- d820907dex991.htm (EX-99.1) — 31KB
- d820907dex992.htm (EX-99.2) — 26KB
- g820907ex10_1.jpg (GRAPHIC) — 19KB
- g820907g11g11.jpg (GRAPHIC) — 144KB
- g820907g12g12.jpg (GRAPHIC) — 215KB
- g820907g13g13.jpg (GRAPHIC) — 148KB
- g820907g14g14.jpg (GRAPHIC) — 156KB
- g820907g15g15.jpg (GRAPHIC) — 172KB
- g820907g16g16.jpg (GRAPHIC) — 146KB
- g820907g17g17.jpg (GRAPHIC) — 143KB
- g820907g18g18.jpg (GRAPHIC) — 134KB
- g820907g19g19.jpg (GRAPHIC) — 142KB
- g820907g20g20.jpg (GRAPHIC) — 161KB
- g820907g21g21.jpg (GRAPHIC) — 163KB
- g820907g22g22.jpg (GRAPHIC) — 160KB
- g820907g23g23.jpg (GRAPHIC) — 88KB
- g820907g24g24.jpg (GRAPHIC) — 201KB
- g820907g25g25.jpg (GRAPHIC) — 222KB
- g820907g26g26.jpg (GRAPHIC) — 174KB
- g820907g27g27.jpg (GRAPHIC) — 213KB
- g820907g28g28.jpg (GRAPHIC) — 173KB
- g820907g29g29.jpg (GRAPHIC) — 169KB
- g820907g30g30.jpg (GRAPHIC) — 124KB
- g820907g31g31.jpg (GRAPHIC) — 29KB
- 0001193125-25-004063.txt ( ) — 4817KB
- spro-20250107.xsd (EX-101.SCH) — 3KB
- spro-20250107_lab.xml (EX-101.LAB) — 18KB
- spro-20250107_pre.xml (EX-101.PRE) — 11KB
- d820907d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1+ Interim Period Agreement, dated January 10, 2025, between the Company and Mr. Shukla. 10.2+ Interim Period Agreement, dated January 10, 2025, between the Company and Ms. Rajavelu. 99.1 Investor Presentation of Spero Therapeutics, Inc., dated January 10, 2025. 99.2 Press Release of Spero Therapeutics, Inc., dated January 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Management contract or compensatory plan. 4 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2025 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Interim President and Chief Executive Officer 5